Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction

Journal of the American College of Cardiology

Volumn 54, Issue 23, 2009, Pages 2174-2179

  Pascual Figal, Domingo A ^a   Ordoñez Llanos, Jordi ^b   Tornel, Pedro L ^a   Vázquez, Rafael ^c   Puig, Teresa ^b   Valdés, Mariano ^a   Cinca, Juan ^b   de Luna, Antoni Bayes ^d   Bayes Genis, Antoni ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^d Institut Català de Ciències Cardiovasculars   (Spain)

Author keywords

B type natriuretic peptide; biomarkers; chronic heart failure; soluble ST2; sudden cardiac death

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SUDDEN DEATH; SYSTOLIC HEART FAILURE;

AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MYOCARDIAL CONTRACTION; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1; RETROSPECTIVE STUDIES; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70449846683     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.041     Document Type: Article

References (36)

1. Uretsky B.F., and Sheahan R.G. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking?. J Am Coll Cardiol 30 (1997) 1589-1597
2. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48 (2006) e247-e346
3. Buxton A.E., Lee K.L., Hafley G.E., et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 106 (2002) 2466-2472
4. Zimetbaum P.J., Buxton A.E., Batsford W., et al. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation 110 (2004) 766-769
5. Doval H.C., Nul D.R., Grancelli H.O., et al., GESICA-GEMA Investigators. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden failure. Circulation 94 (1996) 3198-3203
6. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392-2397
7. Hodges M., Bailey J.J., and Church T.R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 107 (2003) e13
8. Watanabe J., Shiba N., Shinozaki T., et al. Prognostic value of plasma brain natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. J Card Fail 11 (2005) 50-55
9. Blangy H., Sadoul N., Dousset B., et al. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 9 (2007) 724-729
10. Lane R.E., Cowie M.R., and Chow A.W.C. Prediction and prevention of sudden cardiac death in heart failure. Heart 91 (2005) 674-680
11. Tomaselli G.F., and Zipes D.P. What causes sudden death in heart failure?. Circ Res 95 (2004) 754-763
12. Kurosawa K., Li H., Tago K., Iwahana H., et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma 19 (2000) 151-159
13. Weinberg E.O., Shimpo M., De Keulenaer G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106 (2002) 2961-2966
14. Iwahana H., Yanagisawa K., Ito-Kosaka A., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 264 (1999) 397-406
15. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor related protein ST-2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
16. Chackerian A.A., Oldham E.R., Murphy E.E., Schmitz J., Pflanz S., and Kastelein R.A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179 (2007) 2551-2555
17. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., and Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117 (2007) 1538-1549
18. Rakkar R., and Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 (2008) 827-840
19. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109 (2004) 2186-2190
20. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008) 1936-1944
21. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., and Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107 (2003) 721-726
22. Rehman S.U., Mueller T., and Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52 (2008) 1458-1465
23. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., and Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54 (2008) 752-756
24. Bayes-Genis A., Vazquez R., Puig T., et al. Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. Eur J Heart Fail 9 (2007) 802-807
25. Vazquez R., Bayes-Genis A., Cygankiewicz I., et al. The MUSIC risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 30 (2009) 1088-1096
26. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., and Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007) 1453-1457
27. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
28. Tapanainen J.M., Lindgren K.S., Makikallio T.H., Vuolteenaho O., Leppaluoto J., and Huikuri H.V. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 43 (2004) 757-763
29. Apple F.S., Wu A.H., Jaffe A.S., et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure. National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine. Circulation 31 116 (2007) e95-e98
30. Pascual-Figal D.A., Domingo M., Casas T., et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 29 (2008) 1011-1018
31. Januzzi Jr. J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50 (2007) 607-613
32. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14 (2008) 732-738
33. Timmers L., Sluijter J.P., Van Keulen J.K., et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 102 (2008) 257-262
34. Bartunek J., Delrue L., Van Durme, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 52 (2008) 2166-2174
35. Baudino T.A., Carver W., Giles W., and Borg T.K. Cardiac fibroblasts: friend or foe?. Am J Physiol Heart Circ Physiol 291 (2006) H1015-H1026
36. Saxon L.A., Bristow M.R., Boehmer J., et al. Predictors of sudden cardiac death and appropriate shock in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial. Circulation 114 (2006) 2766-2772